Cardiovascular disease (CVD) is the number one cause of death worldwide. Cardiovascular disease occurs usually due to atherosclerosis of large and medium sized arteries and dyslipidemia has been found to be one of the most important contributing factors. Lowering lipids through dietary intervention or pharmacological therapy has been shown to decrease the incidence of atherosclerotic events. Lipotab is a polypharmaceutical herbal drug, which has shown lipid lowering, antioxidant, anti-inflammatory and vasorelaxant activities in various animal models. To evaluate the efficacy and safety of Lipotab in dyslipidemic human subjects a randomized; double blind placebo controlled clinical study was conducted in Clinical Research__ampersandsignnbsp;Unit, Majeedia Hospital, Jamia Hamdard University, New Delhi.__ampersandsignnbsp;Twelve week Lipotab treatment, was discovered significantly effective than placebo in improving lipid profile of the study subjects. The results of the present study suggest that Lipotab is a safe and efficacious drug in treating dyslipidemia. This polypharmaceutical herbal drug can be valuable in prevention of atherosclerosis and cardiovascular disease by antiplatelet, fibrinolytic, antioxidant and cholesterol lowering activities of its various ingredients.